Akademik Veri Yönetim Sistemi
Kocaeli Science Congress 2024 (KOSC-2024), Kocaeli, Türkiye, 2 - 04 Ekim 2024, ss.175-179
Radioisotopes play an important role in many nuclear medicine applications such as cancer diagnosis, research, monitoring and treatment of other biological phenomena. Barium-131 has a suitable half-life of 11.5 days for medical use and is a radioisotope compatible with Single Photon Emission Computed Tomography (SPECT) for nuclear medicine. Due to the similar chemistry and pharmacological properties of the elements barium and radium, barium-131 can be used diagnostically with the therapeutic alpha emitters radium-223 and radium-224. It is therefore expected that the radioisotope barium-131 will be used in the future as part of current approaches to the treatment of bone cancer and bone metastases. The cross sections of the 133Cs(p,3n)131Ba reaction producing barium-131 are calculated for different nuclear parameters and compared with available experimental results.